AI Analysis
AI-generated analysis. Always verify with the original filing.
Cytosorbents delivered modest revenue growth and significantly narrowed losses for fiscal 2025, while executing restructuring actions to advance its path to profitability.
Key Takeaways
1GAAP revenue for fiscal 2025 totaled $37.1M, marking a 4.1% year-over-year increase from fiscal 2024 results.
2Gross profit rose 5.4% year-over-year to $26.5M, resulting in a GAAP gross margin of 71.5% for the full 2025 fiscal year.
3GAAP operating loss narrowed 12.1% year-over-year to $14.7M, supported by cost reduction efforts across clinical and operational functions.
4Net loss improved 60.4% year-over-year to $8.2M, driven by lower clinical trial costs following completion of the STAR-T trial and foreign currency exchange gains.
5Diluted loss per share came in at -$0.13 for fiscal 2025, representing a 65.8% year-over-year improvement from the -$0.38 per share loss reported in fiscal 2024.